Mumbai: This hunt isn’t straightforward – discovering potential winners in a locked down world.

To make certain, analysts have been moderately busy with their scalpel, slashing value targets of greater than 95 per cent of the shares they monitor resulting from lack of earnings visibility.

Nonetheless, choose shares in industries similar to prescribed drugs, chemical compounds and telecom noticed a rise in consensus goal costs. These shares have both benefited or may benefit in a state of affairs the place buyers are looking for security.

Deepak Nitrite has reported an 88 per cent improve in consolidated web revenue at 172.3 crore for the quarter ended March regardless of the lockdown. It could possibly be the beneficiary of extra demand that will come up because of world chemical compounds firms diversifying their sourcing necessities past China.

Laurus Labs, a key provider of differentiated APIs (lively pharmaceutical substances) for antiretroviral (ARV), oncology merchandise and formulation enterprise, would profit from the ahead integration. Equally, Bharti Airtel will profit from do business from home, which has change into the brand new norm now. Ajanta Pharma is well-positioned to profit from the rise in lively drug shortages within the US.


Equally, Eris Lifesciences has benefited from its home play, and really restricted regulatory and foreign money dangers. Alkem Laboratories, with new merchandise launched within the US for higher working leverage, has additionally seen an improve.

ET takes a have a look at 10 such shares which have seen the largest will increase in goal value and can provide 10-30 per cent returns from the present ranges.